NASDAQ:BIOA - Nasdaq - US09077V1008 - Common Stock - Currency: USD
2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | ||||
---|---|---|---|---|---|---|
Revenue | 0.00 | 0.00 | 0.00 | |||
Operating Expenses | 78.19M | 48.40M | 39.97M | |||
Research and Development | 59.04M | 33.89M | 30.52M | |||
Selling, General, and Administrative Expenses | 19.16M | 14.51M | 9.45M | |||
Operating Income | -78.19M | -48.40M | -39.97M | |||
Interest Income/Expense | 7.33M | -15.45M | 247.00K | |||
Non Recurring Items | -250.00K | N/A | N/A | |||
Income Before Taxes | -71.11M | -63.85M | -39.72M | |||
Net Income | -71.11M | -63.85M | -39.72M | |||
EBITDA | -78.03M | -48.24M | -39.84M | |||
Per Share Data | ||||||
EPS Diluted Total Ops | -1.98 | -1.87 | -1.16 | |||
Statistics |
All data in USD